<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001778071</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0002012593</issuerCik>
      <issuerName>Rapport Therapeutics, Inc.</issuerName>
      <secFileNumber>001-42121</secFileNumber>
      <issuerAddress>
        <com:street1>99 HIGH STREET</com:street1>
        <com:street2>SUITE 2100</com:street2>
        <com:city>BOSTON</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02110</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>857-321-8020</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Third Rock Ventures V, L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>10% Stockholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Raymond James &amp; Associates</name>
        <address>
          <com:street1>880 Carillon Parkway</com:street1>
          <com:city>St. Petersburg</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>33716</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>426005</noOfUnitsSold>
      <aggregateMarketValue>17175115.78</aggregateMarketValue>
      <noOfUnitsOutstanding>47792943</noOfUnitsOutstanding>
      <approxSaleDate>04/17/2026</approxSaleDate>
      <securitiesExchangeName>Nasdaq</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common</securitiesClassTitle>
      <acquiredDate>02/21/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Original Issuance</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer-Rapport Therapeutics, Inc.</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>2803200</amountOfSecuritiesAcquired>
      <paymentDate>02/21/2023</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <noticeSignature>
      <noticeDate>04/17/2026</noticeDate>
      <planAdoptionDates>
        <planAdoptionDate>11/21/2025</planAdoptionDate>
      </planAdoptionDates>
      <signature>Melissa Fisher, as duly authorized representative of Raymond James &amp; Associates, Inc., as attorney-in-fact for Keving Gillis</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
